전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved73 programs
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 1

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJuventas Cell Therapy Ltd.Phase 1

CNCT19 CAR-T cell therapy (CNCT19 CAR-T cell therapy)

Autoimmune Hemolytic Anemia; Autologous CD19 CAR-T · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Cervical cancer-specific CAR-T cells (Cervical cancer-specific CAR-T cells)

Cervical Cancer · Cervical Cancer

#CervicalCancer#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleWeill Medical College of Cornel…Phase 3

Higher Dose of Rituximab (Higher Dose of Rituximab)

Immune Thrombocytopenic Purpura · Immune Thrombocytopenic Purpura

#ImmuneThrombocytopenicPurpura#Antibody#Phase3#monoclonal-antibody#Weill
Trials 1Status Active
CGTLimited DatastaleImmune Cell, Inc.Phase 1

ICAR30 T cells (ICAR30 T cells)

Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

CD19 Negative B-cell Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Preclinical

Lentiviral TYF-ARSA correction of patient's autologous HSCs (Lentiviral TYF-ARSA correction of patient's autologous HSCs)

Metachromatic Leukodystrophy (MLD) · Metachromatic Leukodystrophy (MLD)

#MetachromaticLeukodystrophyMLD#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCancer Institute and Hospital, …Phase 1

IDOV-Immune (Oncolytic Virus injection, Oncolytic Virus injection(IDOV-Immune))

Cancer · Cancer

#Cancer#CGT#Phase1#cell-gene-therapy#CAR-T+1
Trials 1Status Active
CGTLimited DatastalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNewcastle UniversityApproved

Solu-medrone, Mabthera (Solu-medrone, Mabthera)

Autoimmune Adrenocortical Failure · Autoimmune Adrenocortical Failure

#AutoimmuneAdrenocorticalFailure#Antibody#Approved#monoclonal-antibody#Newcastle
Trials 1Status Active

3 / 4 pages

← PreviousNext →